{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:34:53Z","timestamp":1787016893046,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZC20230301"],"award-info":[{"award-number":["GZC20230301"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-010"],"award-info":[{"award-number":["2022-PUMCH-B-010"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-023"],"award-info":[{"award-number":["2024-I2M-C&T-B-023"]}]},{"name":"Beijing Natural Science Foundation","award":["L258065"],"award-info":[{"award-number":["L258065"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54855-9","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:32:31Z","timestamp":1780767151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of clinical and pathological characteristics of classic adrenocortical carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Yi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaYang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianHua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuShi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"54855_CR1","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs, T. M. et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49, 2579\u20132586. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034 (2013).","journal-title":"Eur. J. Cancer"},{"key":"54855_CR2","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1210\/jc.2018-00918","volume":"103","author":"SH Tella","year":"2018","unstructured":"Tella, S. H., Kommalapati, A., Yaturu, S. & Kebebew, E. Predictors of survival in adrenocortical carcinoma: An analysis from the National Cancer Database. J. Clin. Endocrinol. Metab. 103, 3566\u20133573. https:\/\/doi.org\/10.1210\/jc.2018-00918 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54855_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.eururo.2011.07.062","volume":"60","author":"L Zini","year":"2011","unstructured":"Zini, L., Porpiglia, F. & Fassnacht, M. Contemporary management of adrenocortical carcinoma. Eur. Urol. 60, 1055\u20131065. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.062 (2011).","journal-title":"Eur. Urol."},{"key":"54855_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3238\/arztebl.2010.0885","volume":"107","author":"S Johanssen","year":"2010","unstructured":"Johanssen, S. et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch. Arztebl. Int. 107, 885\u2013891. https:\/\/doi.org\/10.3238\/arztebl.2010.0885 (2010).","journal-title":"Dtsch. Arztebl. Int."},{"key":"54855_CR5","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/cncr.23886","volume":"113","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria, K. Y. et al. Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 113, 3130\u20133136. https:\/\/doi.org\/10.1002\/cncr.23886 (2008).","journal-title":"Cancer"},{"key":"54855_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102077","volume":"22","author":"HA Yasar","year":"2024","unstructured":"Yasar, H. A. et al. Adrenocortical cancer in the real world: A comprehensive analysis of clinical features and management from the Turkish Oncology Group (TOG). Clin. Genitourin. Cancer 22, 102077. https:\/\/doi.org\/10.1016\/j.clgc.2024.102077 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"54855_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti, A. et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 166, 451\u2013458. https:\/\/doi.org\/10.1530\/EJE-11-0918 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"54855_CR8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip, L. et al. American Association of Endocrine Surgeons guidelines for adrenalectomy: Executive summary. JAMA Surg. 157, 870\u2013877. https:\/\/doi.org\/10.1001\/jamasurg.2022.3544 (2022).","journal-title":"JAMA Surg."},{"key":"54855_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1245\/s10434-022-12711-w","volume":"30","author":"H Nakanishi","year":"2023","unstructured":"Nakanishi, H. et al. Open versus laparoscopic surgery in the management of adrenocortical carcinoma: A systematic review and meta-analysis. Ann. Surg. Oncol. 30, 994\u20131005. https:\/\/doi.org\/10.1245\/s10434-022-12711-w (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"54855_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1210\/jc.2014-3182","volume":"100","author":"F Beuschlein","year":"2015","unstructured":"Beuschlein, F. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J. Clin. Endocrinol. Metab. 100, 841\u2013849. https:\/\/doi.org\/10.1210\/jc.2014-3182 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54855_CR11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41568-023-00623-0","volume":"23","author":"C Ghosh","year":"2023","unstructured":"Ghosh, C., Hu, J. & Kebebew, E. Advances in translational research of the rare cancer type adrenocortical carcinoma. Nat. Rev. Cancer 23, 805\u2013824. https:\/\/doi.org\/10.1038\/s41568-023-00623-0 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"54855_CR12","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"54855_CR13","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966 (2012).","journal-title":"N. Engl. J. Med."},{"key":"54855_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000336134","volume":"88","author":"D Dong","year":"2012","unstructured":"Dong, D., Li, H., Yan, W., Ji, Z. & Mao, Q. Surgical management and clinical prognosis of adrenocortical carcinoma. Urol. Int. 88, 400\u2013404. https:\/\/doi.org\/10.1159\/000336134 (2012).","journal-title":"Urol. Int."},{"key":"54855_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/OTT.S157518","volume":"11","author":"GY Zheng","year":"2018","unstructured":"Zheng, G. Y., Li, H. Z., Deng, J. H., Zhang, X. B. & Wu, X. C. Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: A retrospective comparative study on short-term oncologic prognosis. Onco Targets Ther. 11, 1625\u20131632. https:\/\/doi.org\/10.2147\/OTT.S157518 (2018).","journal-title":"Onco Targets Ther."},{"key":"54855_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/11795549241271657","volume":"19","author":"C Ma","year":"2025","unstructured":"Ma, C., Yang, B. & Mao, Q. Diagnostic and predictive recurrence value of plasma fibrinogen in patients with adrenocortical carcinoma. Clin. Med. Insights Oncol. 19, 11795549241271657. https:\/\/doi.org\/10.1177\/11795549241271657 (2025).","journal-title":"Clin. Med. Insights Oncol."},{"key":"54855_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678. https:\/\/doi.org\/10.1038\/s41587-020-0546-8 (2020).","journal-title":"Nat. Biotechnol."},{"key":"54855_CR18","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"54855_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"54855_CR20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"54855_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0773-7","volume":"21","author":"S Jasim","year":"2019","unstructured":"Jasim, S. & Habra, M. A. Management of adrenocortical carcinoma. Curr. Oncol. Rep. 21, 20. https:\/\/doi.org\/10.1007\/s11912-019-0773-7 (2019).","journal-title":"Curr. Oncol. Rep."},{"key":"54855_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","volume":"44","author":"E Baudin","year":"2015","unstructured":"Baudin, E., Endocrine Tumor Board of Gustave, R. Adrenocortical carcinoma. Endocrinol. Metab. Clin. North Am. 44, 411\u2013434. https:\/\/doi.org\/10.1016\/j.ecl.2015.03.001 (2015).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"54855_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MED.0000000000000056","volume":"21","author":"M Terzolo","year":"2014","unstructured":"Terzolo, M., Zaggia, B., Allasino, B. & De Francia, S. Practical treatment using mitotane for adrenocortical carcinoma. Curr. Opin. Endocrinol. Diabetes Obes. 21, 159\u2013165. https:\/\/doi.org\/10.1097\/MED.0000000000000056 (2014).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"54855_CR24","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2","volume":"92","author":"E Baudin","year":"2001","unstructured":"Baudin, E. et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92, 1385\u20131392. https:\/\/doi.org\/10.1002\/1097-0142(20010915)92:6%3C1385::aid-cncr1461%3E3.0.co;2-2 (2001).","journal-title":"Cancer"},{"key":"54855_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.31916","volume":"125","author":"T Chandrasekar","year":"2019","unstructured":"Chandrasekar, T. et al. The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. Cancer 125, 1050\u20131059. https:\/\/doi.org\/10.1002\/cncr.31916 (2019).","journal-title":"Cancer"},{"key":"54855_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282\u2013326. https:\/\/doi.org\/10.1210\/er.2013-1029 (2014).","journal-title":"Endocr. Rev."},{"key":"54855_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jpedsurg.2013.02.017","volume":"48","author":"JP McAteer","year":"2013","unstructured":"McAteer, J. P., Huaco, J. A. & Gow, K. W. Predictors of survival in pediatric adrenocortical carcinoma: A Surveillance, Epidemiology, and End Results (SEER) program study. J. Pediatr. Surg. 48, 1025\u20131031. https:\/\/doi.org\/10.1016\/j.jpedsurg.2013.02.017 (2013).","journal-title":"J. Pediatr. Surg."},{"key":"54855_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s43587-023-00420-2","volume":"3","author":"KM Warde","year":"2023","unstructured":"Warde, K. M. et al. Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner. Nat. Aging 3, 846\u2013865. https:\/\/doi.org\/10.1038\/s43587-023-00420-2 (2023).","journal-title":"Nat. Aging"},{"key":"54855_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add0422","volume":"8","author":"JJ Wilmouth Jr","year":"2022","unstructured":"Wilmouth Jr., J. J. et al. Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development. Sci. Adv. 8, eadd0422. https:\/\/doi.org\/10.1126\/sciadv.add0422 (2022).","journal-title":"Sci. Adv."},{"key":"54855_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-2006-923808","volume":"114","author":"AC Koschker","year":"2006","unstructured":"Koschker, A. C., Fassnacht, M., Hahner, S., Weismann, D. & Allolio, B. Adrenocortical carcinoma -- improving patient care by establishing new structures. Exp. Clin. Endocrinol. Diabetes. 114, 45\u201351. https:\/\/doi.org\/10.1055\/s-2006-923808 (2006).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"54855_CR31","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/jc.2005-2730","volume":"91","author":"G Abiven","year":"2006","unstructured":"Abiven, G. et al. Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab. 91, 2650\u20132655. https:\/\/doi.org\/10.1210\/jc.2005-2730 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54855_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1677\/erc.1.01130","volume":"14","author":"R Libe","year":"2007","unstructured":"Libe, R., Fratticci, A. & Bertherat, J. Adrenocortical cancer: Pathophysiology and clinical management. Endocr. Relat. Cancer 14, 13\u201328. https:\/\/doi.org\/10.1677\/erc.1.01130 (2007).","journal-title":"Endocr. Relat. Cancer"},{"key":"54855_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.4158\/EP.15.5.450","volume":"15","author":"MA Zeiger","year":"2009","unstructured":"Zeiger, M. A. et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: Executive summary of recommendations. Endocr Pract 15, 450\u2013453. https:\/\/doi.org\/10.4158\/EP.15.5.450 (2009).","journal-title":"Endocr Pract"},{"key":"54855_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMcp065470","volume":"356","author":"WF Young Jr","year":"2007","unstructured":"Young Jr., W. F. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 356, 601\u2013610. https:\/\/doi.org\/10.1056\/NEJMcp065470 (2007).","journal-title":"N. Engl. J. Med."},{"key":"54855_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12672-011-0088-0","volume":"2","author":"M Papotti","year":"2011","unstructured":"Papotti, M. et al. The Weiss score and beyond\u2013Histopathology for adrenocortical carcinoma. Horm. Cancer 2, 333\u2013340. https:\/\/doi.org\/10.1007\/s12672-011-0088-0 (2011).","journal-title":"Horm. Cancer"},{"key":"54855_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13193-020-01205-4","volume":"11","author":"MK Walz","year":"2020","unstructured":"Walz, M. K. et al. Differentiating benign from malignant adrenocortical tumors by a single morphological parameter\u2013A clinicopathological study on 837 adrenocortical neoplasias. Indian J. Surg. Oncol. 11, 705\u2013710. https:\/\/doi.org\/10.1007\/s13193-020-01205-4 (2020).","journal-title":"Indian J. Surg. Oncol."},{"key":"54855_CR37","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1210\/clinem\/dgab866","volume":"107","author":"MR Clay","year":"2022","unstructured":"Clay, M. R., Pinto, E. M., Fishbein, L., Else, T. & Kiseljak-Vassiliades, K. Pathological and genetic stratification for management of adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 107, 1159\u20131169. https:\/\/doi.org\/10.1210\/clinem\/dgab866 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54855_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/PAS.0000000000000943","volume":"42","author":"O Mete","year":"2018","unstructured":"Mete, O., Gucer, H., Kefeli, M. & Asa, S. L. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma. Am. J. Surg. Pathol. 42, 201\u2013213. https:\/\/doi.org\/10.1097\/PAS.0000000000000943 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"54855_CR39","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1007\/s12325-019-01050-0","volume":"36","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Prognostic role of Ki-67 in adrenocortical carcinoma after primary resection: A retrospective mono-institutional study. Adv. Ther. 36, 2756\u20132768. https:\/\/doi.org\/10.1007\/s12325-019-01050-0 (2019).","journal-title":"Adv. Ther."},{"key":"54855_CR40","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1007\/s00259-014-2834-3","volume":"41","author":"S Takeuchi","year":"2014","unstructured":"Takeuchi, S. et al. Impact of (1)(8)F-FDG PET\/CT on the management of adrenocortical carcinoma: Analysis of 106 patients. Eur. J. Nucl. Med. Mol. Imaging 41, 2066\u20132073. https:\/\/doi.org\/10.1007\/s00259-014-2834-3 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"54855_CR41","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle, F. et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 103, 1686\u20131695. https:\/\/doi.org\/10.1210\/jc.2017-02591 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54855_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1 (2015).","journal-title":"Lancet Oncol."},{"key":"54855_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54661-9","volume":"15","author":"YC Zhu","year":"2024","unstructured":"Zhu, Y. C. et al. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm phase 2 trial. Nat. Commun. 15, 10371. https:\/\/doi.org\/10.1038\/s41467-024-54661-9 (2024).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54855-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:51Z","timestamp":1787013951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54855-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54855"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54855-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking Union Medical College Hospital (Feb 2024\/XHYY2024010).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25868"}}